Turning computing heat into a practical heating solution for greenhouses.
Updated
January 8, 2026 6:27 PM
Inside of a workstation computer with red lighting. PHOTO: UNSPLASH
Most computing systems have one unavoidable side effect: they get hot. That heat is usually treated as a problem and pushed away using cooling systems. Canaan Inc., a technology company that builds high-performance computing machines, is now showing how that same heat can be reused instead of wasted.
In a pilot project in Manitoba, Canada, Canaan is working with greenhouse operator Bitforest Investment to recover heat generated by its computing systems. Rather than focusing only on computing output, the project looks at a more basic question—what happens to all the heat these machines produce and can it serve a practical purpose?
The idea is simple. Canaan’s computers run continuously and naturally generate heat. Instead of releasing that heat into the environment, the system captures it and uses it to warm water. That warm water is then fed into the greenhouse’s existing heating system. As a result, the greenhouse needs less additional energy to maintain the temperatures required for plant growth.
This is enabled through liquid cooling. Instead of using air to cool the machines, a liquid circulates through the system and absorbs heat more efficiently. Because liquid retains heat better than air, the recovered water reaches temperatures that are suitable for industrial use. In effect, the computing system supports greenhouse heating while continuing to perform its primary computing function.
What makes this approach workable is that it integrates with existing infrastructure. The recovered heat does not replace the greenhouse’s boilers but supplements them. By preheating the water that enters the boiler system, the overall energy demand is reduced. Based on current assumptions, Canaan estimates that a significant portion of the electricity used by the servers can be recovered as usable heat, though actual results will be confirmed once the system is fully operational.
This matters because heating is one of the largest energy expenses for commercial greenhouses, particularly in colder regions like Canada. Many facilities still rely heavily on fossil-fuel-based heating and policies such as carbon pricing are encouraging lower-emission alternatives. Reusing computing heat offers a way to improve efficiency without requiring a complete overhaul of existing systems.
The project is planned to run for an initial two-year period, allowing Canaan to evaluate real-world performance factors such as reliability, system stability and maintenance needs. These findings will help determine whether the model can be replicated in other agricultural or industrial settings.
More broadly, the initiative reflects a shift in how computing infrastructure can be designed. Instead of operating as energy-intensive systems isolated from everyday use, computing equipment can contribute to real-world applications. Canaan’s greenhouse pilot highlights how excess heat—often seen as a by-product—can become part of a more efficient and thoughtful energy loop.
In doing so, the project suggests that improving sustainability in technology is not only about reducing energy consumption, but also about finding smarter ways to reuse the energy already being generated.
Keep Reading
A closer look at how machine intelligence is helping doctors see cancer in an entirely new light.
Updated
January 8, 2026 6:33 PM
Serratia marcescens colonies on BTB agar medium. PHOTO: UNSPLASH
Artificial intelligence is beginning to change how scientists understand cancer at the cellular level. In a new collaboration, Bio-Techne Corporation, a global life sciences tools provider, and Nucleai, an AI company specializing in spatial biology for precision medicine, have unveiled data from the SECOMBIT clinical trial that could reshape how doctors predict cancer treatment outcomes. The results, presented at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting, highlight how AI-powered analysis of tumor environments can reveal which patients are more likely to benefit from specific therapies.
Led in collaboration with Professor Paolo Ascierto of the University of Napoli Federico II and Istituto Nazionale Tumori IRCCS Fondazione Pascale, the study explores how spatial biology — the science of mapping where and how cells interact within tissue — can uncover subtle immune behaviors linked to survival in melanoma patients.
Using Bio-Techne’s COMET platform and a 28-plex multiplex immunofluorescence panel, researchers analyzed 42 pre-treatment biopsies from patients with metastatic melanoma, an advanced stage of skin cancer. Nucleai’s multimodal AI platform integrated these imaging results with pathology and clinical data to trace patterns of immune cell interactions inside tumors.
The findings revealed that therapy sequencing significantly influences immune activity and patient outcomes. Patients who received targeted therapy followed by immunotherapy showed stronger immune activation, marked by higher levels of PD-L1+ CD8 T-cells and ICOS+ CD4 T-cells. Those who began with immunotherapy benefited most when PD-1+ CD8 T-cells engaged closely with PD-L1+ CD4 T-cells along the tumor’s invasive edge. Meanwhile, in patients alternating between targeted and immune treatments, beneficial antigen-presenting cell (APC) and T-cell interactions appeared near tumor margins, whereas macrophage activity in the outer tumor environment pointed to poorer prognosis.
“This study exemplifies how our innovative spatial imaging and analysis workflow can be applied broadly to clinical research to ultimately transform clinical decision-making in immuno-oncology”, said Matt McManus, President of the Diagnostics and Spatial Biology Segment at Bio-Techne.
The collaboration between the two companies underscores how AI and high-plex imaging together can help decode complex biological systems. As Avi Veidman, CEO of Nucleai, explained, “Our multimodal spatial operating system enables integration of high-plex imaging, data and clinical information to identify predictive biomarkers in clinical settings. This collaboration shows how precision medicine products can become more accurate, explainable and differentiated when powered by high-plex spatial proteomics – not limited by low-plex or H&E data alone”.
Dr. Ascierto described the SECOMBIT trial as “a milestone in demonstrating the possible predictive power of spatial biomarkers in patients enrolled in a clinical study”.
The study’s broader message is clear: understanding where immune cells are and how they interact inside a tumor could become just as important as knowing what they are. As AI continues to map these microscopic landscapes, oncology may move closer to genuinely personalized treatment — one patient, and one immune network, at a time.